Form 4: Monopar Director Lavina Talukdar Granted Stock Options

Monopar Therapeutics director Lavina Talukdar received a grant of 2,924 stock options with an exercise price of $75.94, vesting quarterly through 2026.

Summary

• Lavina Talukdar, a Director of Monopar Therapeutics (MNPR), was granted 2,924 stock options.
• The options have an exercise price of $75.94 per share.
• The transaction date for the grant was December 2, 2025.
• The options will expire on December 2, 2035.
• The options vest quarterly at 25% on March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026.
• Following this transaction, Lavina Talukdar beneficially owns 2,924 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a routine compensation event that aligns management incentives with shareholder interests, which is generally viewed as a neutral to slightly positive governance practice.

Positives

• The grant of stock options aligns the director's interests with long-term shareholder value creation.
• The vesting schedule provides an incentive for continued service and performance over the next year.

Negatives

• No direct negatives are apparent from this routine compensation filing.

Future Outlook

NA

Industry Context

This is a standard equity compensation practice for directors in the biotechnology and pharmaceutical industry, aiming to incentivize long-term commitment and align interests with shareholders.

Comparison to Industry Standards

• Granting stock options to non-employee directors is a common practice across publicly traded companies, including those in the biotech sector, to attract and retain qualified board members.
• The vesting schedule over approximately one year is typical for director grants, encouraging continued oversight and strategic contribution.
• The exercise price being set at the market price on the grant date (implied by the lack of a stated discount) is standard for incentive stock options.

Related Party Transactions

• The grant of stock options to Lavina Talukdar, a Director of Monopar Therapeutics, constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant of options could lead to minor dilution if exercised, but it also aims to align the director's interests with long-term shareholder value.

Next Steps

• The stock options will vest quarterly, with 25% vesting on March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026.
• The director may choose to exercise these options at any time after vesting and before the expiration date of December 2, 2035, assuming the stock price is above the exercise price of $75.94.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a director and does not provide sufficient information to warrant a change in investment recommendation. It is a standard governance practice to align director incentives with shareholder interests.

Keywords

Monopar Therapeutics, MNPR, Lavina Talukdar, stock options, director compensation, SEC Form 4, insider transaction, equity grant, vesting schedule